Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036 - AUPH News | RalliesAurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036
A
AUPH• Settlement sets generic entry date and preserves patent claims
- Aurinia reached a settlement with Teva over U.S. patent litigation tied to Teva’s planned generic voclosporin 7.9 mg capsules.
- Teva stipulated Aurinia U.S. Patent Nos. 10,286,036 and 11,622,991 are valid and enforceable, and that they expire in December 2037.
- Generic launch is barred before Dec. 7, 2036, unless defined contingencies trigger earlier entry.
- U.S. marketing remains contingent on FDA approval for Teva’s generic voclosporin product.
- Separate patent suits continue in New Jersey against other generic challengers.
•
